Imran Alibhai, Ph.D., Chief Executive Officer

Prior to becoming CEO of Tvardi, Dr. Alibhai was a Senior Vice President and Managing Director of DNAtrix, a clinical-stage biotech company focused on oncolytic viruses for cancer. During his tenure at DNAtrix, the company secured multiple financing rounds, initiated a Phase 2 immuno-oncology collaboration with Merck, and advanced a next-generation armed virus into the clinic. He previously worked as an investment banker in PJ Solomon's Healthcare Advisory Group, concentrating on M&A transactions in science-based markets. Dr. Alibhai also held roles as Senior Director at Alexandria Venture Investments, where he managed investments in emerging healthcare companies, and directed investments for MPM Capital's BioEquities hedge fund. He began his career in early-stage venture capital at the Accelerator Corp., gaining experience in company formation and management.

Dan Conn, J.D., M.B.A., Chief Financial Officer

Mr. Conn brings a comprehensive background in corporate law, finance, and business management. He started his career as an M&A and securities lawyer before transitioning to investment banking. As an investment banker, he served as an Executive Director at Morgan Stanley and a Director at PJ Solomon, where he focused on M&A, restructuring, and financing transactions across the life sciences and other sectors. Mr. Conn also worked on the buy side, investing in various industries, including life sciences, as a Vice President and Portfolio Manager at D.E. Shaw & Co and later as a Senior Vice President and Portfolio Manager at Brookfield Asset Management. His recent focus has been on operational aspects, directing the development and monetization of intellectual property rights.

John Kauh, M.D., Chief Medical Officer

Dr. Kauh is a board-certified medical oncologist with demonstrated leadership in both early and late-phase drug development. His experience includes guiding US and EU regulatory submissions for drug approval.

Joseph Chen, Ph.D., Vice President, CMC

Dr. Chen possesses 25 years of experience in the Chemistry, Manufacturing, and Controls (CMC) development of drug substances and products. He has extensive expertise in both technical leadership and management oversight for CMC development and manufacturing, both in-house and with Contract Manufacturing Organizations (CMOs). Prior to joining Tvardi, he held positions of increasing responsibility at Boehringer Ingelheim, Tanox, Johnson-Johnson, and Lexicon Pharmaceuticals, leading CMC development for numerous pharmaceutical and biological products.

Stephen O'Brien, CPA, VP, Finance and Corporate Controller

Mr. O'Brien has over 20 years of experience in accounting and financial reporting within the life sciences industry, working with both private and public companies. He was responsible for financial reporting at Eyetech Pharmaceuticals and 3-Dimensional Pharmaceuticals, where he played a role in their IPO processes and managed ongoing public reporting after their listings.

Key Risks to Tvardi Therapeutics

1. Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Tvardi Therapeutics' success is heavily dependent on the successful outcome of its ongoing clinical trials and subsequent regulatory approvals for its product candidates. The company's lead product candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). A significant concern is the reported failure of the lead lung disease candidate to show clinical benefit in preliminary Phase 2 REVERT trial data, which led to a significant stock decline. Negative results from ongoing or future clinical trials, or the inability to obtain regulatory approval, would severely impact the company's viability and stock performance.
2. Financial Sustainability and Funding Risk: Tvardi Therapeutics exhibits signs of financial strain, having reported a deeply negative net margin of -678.79% and a return on equity of -565.83%. These metrics raise serious concerns about the company's ability to sustain operations long enough to achieve clinical milestones and commercialize its products. The company went public in April 2025 through a merger with Cara Therapeutics, a move that provided access to critical funding required to advance its pipeline programs. However, continued heavy investment in clinical development without a clear path to profitability or sustained funding could jeopardize its long-term operations.